CRISPR/Cas9 technology has revolutionized gene therapy by offering a precise and efficient method of DNA editing. However, the challenge lies in developing safe and effective delivery systems for CRISPR/Cas9 constructs to target specific genes without causing off-target effects. Nanoparticles (NPs) have emerged as a promising solution to address this challenge by efficiently delivering CRISPR-Cas9 elements to maximize their therapeutic effectiveness. This review explores the recent advancements in NP-based delivery systems for CRISPR/Cas9 genome editing therapeutics.
The CRISPR/Cas9 system, originating from prokaryotic adaptive immune defense mechanisms, consists of CRISPR RNA (crRNA) guiding the Cas9 endonuclease to target specific DNA sequences for editing. This system offers a versatile tool for precise genome editing in eukaryotic cells, with higher success rates compared to other editing methods like meganucleases, zinc finger nucleases, and transcription activator-like effector nucleases. The growing interest in CRISPR/Cas9 is evident from the significant increase in publications utilizing this technology for gene editing.
Clinical trials utilizing CRISPR/Cas9 therapy have commenced, primarily focusing onex vivogenome editing of cells before reintroducing them into patients. For direct in vivo delivery of CRISPR/Cas9 systems, safe and efficient carrier systems are essential. This has prompted extensive research into developing non-viral vectors, such as NPs, for delivering CRISPR-Cas9 elements to target cells and tissues. NPs offer advantages like targeted delivery, cargo protection, and scalability, making them attractive for clinical translation.
Various strategies and barriers exist in CRISPR/Cas9 delivery systems, including the form of CRISPR/Cas9 components (e.g., Cas9 protein, plasmids, mRNA, or RNPs) and the need for optimal compatibility within NP formulations. Different NP-based delivery approaches, such as liposomal/lipid-based NPs, polymeric NPs/polyplexes, and cell-penetrating peptides, have been explored for CRISPR/Cas9 delivery. These NPs must navigate cellular uptake mechanisms, endosomal escape, and nuclear translocation to ensure efficient gene editing.
Studies have demonstrated the effectiveness of lipid-based NPs in delivering CRISPR-Cas9 components, showcasing high editing efficiencies in targeting specific genes likePcsk9. The use of chemically modified sgRNAs andCas9mRNA in lipid NPs has shown significant editing outcomes in liver cells, highlighting the potential for treating diseases like familial hypercholesterolemia. Additionally, lipid-like NPs incorporating chalcogen-containing lipidoids have shown promise in achieving comparable editing efficiencies to commercial transfection reagents while minimizing toxicity.
In conclusion, NP-based delivery systems offer a promising avenue for enhancing the therapeutic potential of CRISPR/Cas9 genome editing. By addressing key challenges such as cellular uptake, endosomal escape, and nuclear translocation, NPs can optimize the delivery of CRISPR-Cas9 elements for precise and efficient gene editing. Continued research and development in this field hold great promise for advancing the clinical applications of CRISPR/Cas9 technology.
- NPs provide targeted delivery, cargo protection, and scalability for CRISPR-Cas9 therapeutics.
- Lipid-based NPs have shown high editing efficiencies in targeting specific genes likePcsk9.
- Chemically modified sgRNAs andCas9mRNA in lipid NPs offer significant editing outcomes with minimal toxicity.
- Research on lipid-like NPs incorporating chalcogen-containing lipidoids shows promise for achieving efficient editing while reducing toxicity.
Tags: genome editing, drug delivery, cell culture, formulation, clinical trials, gene therapy, viral vectors
Read more on pmc.ncbi.nlm.nih.gov